Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 106

1.

Overprescription of antibiotics in patients with community-acquired pneumonia in the intensive care unit.

Hooten R, Luis Marquez J, Goldlist K, Urcis R, Adams M, Matthias KR, Nix DE, Al Mohajer M.

Avicenna J Med. 2019 Jul-Sep;9(3):107-110. doi: 10.4103/ajm.AJM_189_18.

2.

Current Concepts and Future Directions in the Pharmacology and Treatment of Coccidioidomycosis.

Thompson GR 3rd, Lewis JS 2nd, Nix DE, Patterson TF.

Med Mycol. 2019 Feb 1;57(Supplement_1):S76-S84. doi: 10.1093/mmy/myy029. Review.

PMID:
30690601
3.

Are Teaching Hospitals Treated Fairly in the Hospital-Acquired Condition Reduction Program?

Al Mohajer M, Joiner KA, Nix DE.

Acad Med. 2018 Dec;93(12):1827-1832. doi: 10.1097/ACM.0000000000002399.

PMID:
30095455
4.

Knowledge, attitude, and practices associated with the diagnosis and management of skin and soft-tissue infections among medical students, residents, and attending physicians.

Beatty N, August J, Saenz JA, Nix DE, Matthias KR, Mohajer MA.

Avicenna J Med. 2018 Jul-Sep;8(3):104-106. doi: 10.4103/ajm.AJM_200_17.

5.

Influenza vaccine availability at urgent care centers in the state of Arizona.

Beatty NL, Hager KM, McKeown KR, Mora F, Matthias KR, Nix DE, Mohajer MA.

Am J Infect Control. 2018 Aug;46(8):946-948. doi: 10.1016/j.ajic.2018.02.005. Epub 2018 Mar 30.

PMID:
29609855
6.

Impact of requiring re-authorization of restricted antibiotics on day 3 of therapy.

Eljaaly K, Elarabi S, Alshehri S, Nix DE.

J Antimicrob Chemother. 2018 Feb 1;73(2):527-530. doi: 10.1093/jac/dkx384.

PMID:
29077862
7.

Should estimates of glomerular filtration rate and creatinine clearance be indexed to body surface area for drug dosing?

Nix DE, Mayersohn M, Erstad BL.

Am J Health Syst Pharm. 2017 Nov 1;74(21):1814-1819. doi: 10.2146/ajhp160467. Epub 2017 Sep 25. No abstract available.

PMID:
28947625
8.

Does Everything That's Counted Count? Value of Inflammatory Markers for Following Therapy and Predicting Outcome in Diabetic Foot Infection.

Ong E, Farran S, Salloum M, Gardner S, Giovinco N, Armstrong DG, Matthias KR, Nix DE, Al Mohajer M.

Int J Low Extrem Wounds. 2017 Jun;16(2):104-107. doi: 10.1177/1534734617700539. Epub 2017 Apr 9.

PMID:
28682724
9.

Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis.

Eljaaly K, Alshehri S, Aljabri A, Abraham I, Al Mohajer M, Kalil AC, Nix DE.

BMC Infect Dis. 2017 Jun 2;17(1):385. doi: 10.1186/s12879-017-2495-5.

10.

Vaginal Mesh Removal Outcomes: Eight Years of Experience at an Academic Hospital.

Cardenas-Trowers OO, Malekzadeh P, Nix DE, Hatch KD.

Female Pelvic Med Reconstr Surg. 2017 Nov/Dec;23(6):382-386. doi: 10.1097/SPV.0000000000000419.

PMID:
28430726
11.

Improving the knowledge of students and physicians regarding appropriate use of antibiotics for respiratory infections through an online educational module.

Al Mohajer M, Matthias KR, Nix DE.

Am J Infect Control. 2017 Jan 1;45(1):e15-e17. doi: 10.1016/j.ajic.2016.09.027. Epub 2016 Nov 11.

PMID:
27839751
12.

Voriconazole Dosing in Obese Patients.

Eljaaly K, Nix DE.

Clin Infect Dis. 2016 Jul 15;63(2):286-7. doi: 10.1093/cid/ciw252. Epub 2016 Apr 24. No abstract available.

PMID:
27114378
13.

Stability of Ampicillin in Normal Saline and Buffered Normal Saline.

Maher M, Jensen KJ, Lee D, Nix DE.

Int J Pharm Compd. 2016 Jul-Aug;20(4):338-342.

PMID:
28333679
14.

Modeling nikkomycin Z dosing and pharmacology in murine pulmonary coccidioidomycosis preparatory to phase 2 clinical trials.

Shubitz LF, Trinh HT, Perrill RH, Thompson CM, Hanan NJ, Galgiani JN, Nix DE.

J Infect Dis. 2014 Jun 15;209(12):1949-54. doi: 10.1093/infdis/jiu029. Epub 2014 Jan 12.

15.

Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis.

Nguyen C, Barker BM, Hoover S, Nix DE, Ampel NM, Frelinger JA, Orbach MJ, Galgiani JN.

Clin Microbiol Rev. 2013 Jul;26(3):505-25. doi: 10.1128/CMR.00005-13. Review.

16.

Efficacy of Nikkomycin Z for respiratory coccidioidomycosis in naturally infected dogs.

Shubitz LF, Roy ME, Nix DE, Galgiani JN.

Med Mycol. 2013 Oct;51(7):747-54. doi: 10.3109/13693786.2013.770610. Epub 2013 Mar 14.

PMID:
23488972
17.

Poor absorption of high-dose posaconazole in pediatric bone marrow transplant patients.

Matthias KR, Nix DE, Peloquin CA, Graham ML.

Ann Pharmacother. 2012 Sep;46(9):e22. doi: 10.1345/aph.1Q456. Epub 2012 Aug 7.

PMID:
22872751
18.

Vancomycin clearance in overweight and obese patients.

Nix DE, Matthias KR, Erstad BL.

Am J Health Syst Pharm. 2011 Oct 1;68(19):1776-7; author reply 1777-8. doi: 10.2146/ajhp110214. No abstract available.

PMID:
21930634
19.

Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation.

Nix DE, Matthias KR.

J Antimicrob Chemother. 2010 Jun;65(6):1311-2. doi: 10.1093/jac/dkq116. Epub 2010 Apr 8. No abstract available.

PMID:
20378673
20.

Vancomycin dosing for pneumonia in critically ill trauma patients.

Patanwala AE, Norris CJ, Nix DE, Kopp BJ, Erstad BL.

J Trauma. 2009 Oct;67(4):802-4. doi: 10.1097/TA.0b013e31818e90d2.

PMID:
19820588
21.

Time to positive culture and identification for Candida blood stream infections.

Fernandez J, Erstad BL, Petty W, Nix DE.

Diagn Microbiol Infect Dis. 2009 Aug;64(4):402-7. doi: 10.1016/j.diagmicrobio.2009.04.002. Epub 2009 May 15.

PMID:
19446982
22.

Pharmacokinetics of nikkomycin Z after single rising oral doses.

Nix DE, Swezey RR, Hector R, Galgiani JN.

Antimicrob Agents Chemother. 2009 Jun;53(6):2517-21. doi: 10.1128/AAC.01609-08. Epub 2009 Apr 6.

23.

End-of-procedure cefazolin concentrations after administration for prevention of surgical-site infection.

Koopman E, Nix DE, Erstad BL, Demeure MJ, Hayes MM, Ruth JT, Matthias KR.

Am J Health Syst Pharm. 2007 Sep 15;64(18):1927-34.

PMID:
17823104
24.

Prophylactic gatifloxacin therapy in prevention of bacterial keratitis in a rabbit laser in situ keratomileusis model.

Slade DS, Friday JW, Snyder RW, Nix DE, Kleinert LB, Patula VB.

J Cataract Refract Surg. 2007 May;33(5):888-92.

PMID:
17466866
25.

Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections.

Patanwala AE, Erstad BL, Nix DE.

Curr Med Res Opin. 2007 Jan;23(1):185-93.

PMID:
17257479
26.

A pilot study of an anti-MRSA bio-engineered lacteal complex (anti-MRSA BLC) in a murine septicemia model.

Stoff JA, Nix DE, DeYoung DW.

Immunopharmacol Immunotoxicol. 2006;28(4):601-7.

PMID:
17190737
27.

Estimation of creatinine clearance in end-stage liver disease.

Nix DE, Erstad BL, Nakazato PZ, Barletta JF, Matthias KR, Krueger TS.

Ann Pharmacother. 2006 May;40(5):900-8. Epub 2006 May 2.

PMID:
16670359
28.

Accuracy and reproducibility of small-volume injections from various-sized syringes.

Erstad AJ, Erstad BL, Nix DE.

Am J Health Syst Pharm. 2006 Apr 15;63(8):748-50. No abstract available.

PMID:
16595816
29.

Pharmacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid.

Nix DE, Adam RD, Auclair B, Krueger TS, Godo PG, Peloquin CA.

Tuberculosis (Edinb). 2004;84(6):365-73.

PMID:
15525560
30.

Effect of ertapenem protein binding on killing of bacteria.

Nix DE, Matthias KR, Ferguson EC.

Antimicrob Agents Chemother. 2004 Sep;48(9):3419-24.

31.

Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections.

Kopp BJ, Nix DE, Armstrong EP.

Ann Pharmacother. 2004 Sep;38(9):1377-82. Epub 2004 Jul 20.

PMID:
15266044
32.

Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians.

Nix DE, Majumdar AK, DiNubile MJ.

J Antimicrob Chemother. 2004 Jun;53 Suppl 2:ii23-8. Review.

PMID:
15150180
33.

Severe cellulitis/myositis caused by Stenotrophomonas maltophilia.

Downhour NP, Petersen EA, Krueger TS, Tangella KV, Nix DE.

Ann Pharmacother. 2002 Jan;36(1):63-6.

PMID:
11816260
34.

Pharmacokinetics of para-aminosalicylic acid granules under four dosing conditions.

Peloquin CA, Zhu M, Adam RD, Singleton MD, Nix DE.

Ann Pharmacother. 2001 Nov;35(11):1332-8.

PMID:
11724078
35.

Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids.

Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA.

Pharmacotherapy. 2001 Aug;21(8):891-7.

PMID:
11718495
36.

In vitro susceptibility of Stenotrophomonas maltophilia to various antimicrobial combinations.

Krueger TS, Clark EA, Nix DE.

Diagn Microbiol Infect Dis. 2001 Sep-Oct;41(1-2):71-8.

PMID:
11687317
37.

Pharmacokinetics of ethionamide administered under fasting conditions or with orange juice, food, or antacids.

Auclair B, Nix DE, Adam RD, James GT, Peloquin CA.

Antimicrob Agents Chemother. 2001 Mar;45(3):810-4.

38.

Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens.

Barletta JF, Johnson SB, Nix DE, Nix LC, Erstad BL.

J Trauma. 2000 Nov;49(5):869-72.

PMID:
11086778
39.

Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids.

Peloquin CA, Namdar R, Dodge AA, Nix DE.

Int J Tuberc Lung Dis. 1999 Aug;3(8):703-10.

PMID:
10460103
40.

The effect of low-dose cimetidine (200 mg twice daily) on the pharmacokinetics of theophylline.

Nix DE, Di Cicco RA, Miller AK, Boyle DA, Boike SC, Zariffa N, Jorkasky DK, Schentag JJ.

J Clin Pharmacol. 1999 Aug;39(8):855-65.

PMID:
10434239
41.

Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose.

Birmingham MC, Guarino R, Heller A, Wilton JH, Shah A, Hejmanowski L, Nix DE, Schentag JJ.

J Antimicrob Chemother. 1999 Mar;43 Suppl A:43-8.

PMID:
10225571
42.

Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids.

Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE.

Antimicrob Agents Chemother. 1999 Mar;43(3):568-72.

43.

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids.

Peloquin CA, Namdar R, Singleton MD, Nix DE.

Chest. 1999 Jan;115(1):12-8. Erratum in: Chest 1999 May;115(5):1485.

PMID:
9925057
44.

Pharmacokinetics of pyrazinamide under fasting conditions, with food, and with antacids.

Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, James GT, Nix DE.

Pharmacotherapy. 1998 Nov-Dec;18(6):1205-11.

PMID:
9855317
45.

Pharmacodynamic interactions of ciprofloxacin, piperacillin, and piperacillin/tazobactam in healthy volunteers.

Strenkoski-Nix LC, Forrest A, Schentag JJ, Nix DE.

J Clin Pharmacol. 1998 Nov;38(11):1063-71.

PMID:
9824789
46.

Intrapulmonary concentrations of antimicrobial agents.

Nix DE.

Infect Dis Clin North Am. 1998 Sep;12(3):631-46, viii. Review.

PMID:
9779382
47.

Pharmacodynamic interactions of antibiotics alone and in combination.

Schentag JJ, Strenkoski-Nix LC, Nix DE, Forrest A.

Clin Infect Dis. 1998 Jul;27(1):40-6. Review.

PMID:
9675447
48.

Assessment of the enzymuria resulting from gentamicin alone and combinations of gentamicin with various beta-lactam antibiotics.

Nix DE, Thomas JK, Symonds WT, Spivey JM, Wilton JH, Gagliardi NC, Schentag JJ.

Ann Pharmacother. 1997 Jun;31(6):696-703.

PMID:
9184707
49.

Pharmacodynamic modeling of the in vivo interaction between cefotaxime and ofloxacin by using serum ultrafiltrate inhibitory titers.

Nix DE, Wilton JH, Hyatt J, Thomas J, Strenkoski-Nix LC, Forrest A, Schentag JJ.

Antimicrob Agents Chemother. 1997 May;41(5):1108-14.

50.

Comparative pharmacokinetics of oral ceftibuten, cefixime, cefaclor, and cefuroxime axetil in healthy volunteers.

Nix DE, Symonds WT, Hyatt JM, Wilton JH, Teal MA, Reidenberg P, Affrime MB.

Pharmacotherapy. 1997 Jan-Feb;17(1):121-5.

PMID:
9017772

Supplemental Content

Support Center